Amman, May 19 (Petra) -- The Jordan Food and Drug Administration (JFDA), through its Rational Drug Use and Pharmacovigilance Department, has achieved a qualitative milestone in drug safety by discovering an error in the medical leaflet of an innovator product manufactured by a global pharmaceutical company and marketed across Europe with the same leaflet.

According to a JFDA statement released on Tuesday, the discrepancy was spotted during a routine review of an update to the product's leaflet. Based on an intensive scientific study and an evaluation of the drug's data and specifications, the pharmacovigilance department raised its observations. Consequently, the manufacturing company was notified through its local agent in Jordan. Upon reviewing the notice, the manufacturer confirmed the validity of Jordan's findings, leading to the withdrawal of the innovator drug's leaflet from all registered global markets to carry out the necessary updates in response to the JFDA's feedback.

During an honoring ceremony for pharmacovigilance specialist Ghadir Al-Qawasmi, JFDA Director General Rana Obeidat praised Al-Qawasmi's pioneering role in pharmacovigilance and drug safety data analysis. Obeidat noted that this effort directly contributed to regional health authorities adopting the update and implementing it across circulated medical leaflets, reflecting the advanced scientific and technical expertise housed within the administration.

Obeidat emphasized that this achievement embodies the efficiency and excellence of the administration's experts on an international level. She added that it underscores the strength of Jordan's regulatory frameworks and technical procedures, reinforcing the JFDA's role as a trusted reference authority in drug regulation that ensures the availability of safe and effective medicines in line with global best practices. This milestone further bolsters local, regional, and international confidence in the JFDA and its specialized technical capabilities.

//Petra// AF